Introduction {#s1}
============

Chronic CD8^+^ T-cell expansions, typically composed of large granular lymphocytes (LGL), are reactive (non clonal) or clonal diseases associated with various pathological conditions. Non clonal CD8^+^ T-cell expansions can result in parotid gland swelling and other pseudotumoral organ infiltration in human immunodeficiency virus (HIV)-infected patients, a syndrome termed DILS (diffuse infiltration of CD8^+^ T-cell lymphocytes syndrome). In the setting of allogeneic hematopoietic stem cell transplantation (allo-SCT), chronic CD8^+^ T-cell expansions were identified in long term survivors with chronic graft versus host disease (GVHD) and lymphocytic alveolitis [@pone.0091505-Itescu1]--[@pone.0091505-Nitta1]. Chronic CD8^+^ T-cell expansions were also associated with cytopenia(s) of unexplained origin, such as chronic immunological neutropenia (CIN) and pure red cell aplasia (PRCA), typically in patients with a connective tissue disease [@pone.0091505-Coppo1]--[@pone.0091505-Akhtari1]. In these forms, CD8^+^ T-cell expansions may be non clonal, or clonal and then termed LGL leukemia. This latter is characterized by a monoclonal rearrangement of αβ or γδ T-cell receptor (TCR) loci [@pone.0091505-Focosi1]. The distinction between reactive, non clonal CD8^+^ T-cell expansions and LGL leukemia remains challenging but mandatory since their management and their prognosis differ.

Expanded CD8^+^ T lymphocytes, either clonal or not, represent activated cytotoxic T lymphocytes at a terminal stage of their differentiation with evidence of immunological senescence, which have usually lost their cytotoxic properties to become effector memory "regulatory" T lymphocytes [@pone.0091505-Brenchley1], [@pone.0091505-Wang1], [@pone.0091505-Yamashita1]. They usually express the CD57 antigen, a surrogate marker of this population, which is also expressed in natural killer cells, and rarely in CD4^+^ T-cells and TCRγδ^+^ T-cells [@pone.0091505-Focosi1]. CD8^+^/CD57^+^ lymphocytes represent 1 to 15% of total lymphocytes in healthy subjects and increase from birth to the elderly [@pone.0091505-Focosi1], [@pone.0091505-Batliwalla1]. These lymphocytes have oligoclonal restrictions of Vβ and Jβ chains, consistent with an antigen-driven process [@pone.0091505-Dwyer1]. In this regard, a CD8^+^/CD57^+^ lymphocytes expansion typically occurs in patients with chronic viral infections and autoimmune diseases, suggesting the chronic stimulation of CD8^+^/CD28^+^/CD57^−^ lymphocytes by exogenous (mostly infection-related), or autologous antigens. In this regard, HIV and cytomegalovirus (CMV) were involved as contributing factors in this process [@pone.0091505-Dock1], [@pone.0091505-Chou1]. Paralleling chronic antigen stimulation, these CD8^+^ T-cells acquire a poor capacity to proliferate in standard conditions in relation with the loss of CD28, whereas CD57 antigen becomes expressed at their surface, consistent with an advanced differentiation state and replicative senescence [@pone.0091505-Dock1], [@pone.0091505-dAngeac1]--[@pone.0091505-Strioga1]. The role of these lymphocytes is only partially understood but they could mainly exert immunosuppressive functions which mediators remain to be defined. Alternatively, they were involved in anti-HIV immune response [@pone.0091505-Smith1], [@pone.0091505-Itescu3], as well as in systemic inflammation with progressive tissue damage [@pone.0091505-Dock1], [@pone.0091505-Kaplan1].

So far, the clinical spectrum of chronic CD8^+^ T-cell expansions remains ill-defined and their management is not consensual, especially in the reactive forms. Here, we performed a retrospective analysis of all CD8^+^ T-cell expansions resulting in tissue infiltration and/or cytopenia(s) over a 6 year period in a single institution. Our aim was to extend the spectrum of clinical features observed in CD8^+^ T-cell expansions and to define relevant indications for which the identification of a CD8^+^ T-cell expansion can be useful in clinical practice. We also provide original insights into the management of this rare condition.

10.1371/journal.pone.0091505.t001

###### CD8^+^ T-cell expansion with tissue infiltration in the context of HIV infection.

![](pone.0091505.t001){#pone-0091505-t001-1}

  Patient    Sex/Age        Underlyingconditions                      Clinical manifestations                                Treatment and outcome                   FU(months)
  --------- --------- --------------------------------- ---------------------------------------------------- ------------------------------------------------------ ------------
  1           M/65              HIV infection             Diarrhea and hepatomegaly withrectal, liver and                ART and symptomatic measures:                   50
                            Chronic HBV infection               cutaneous CD8^+^ T-cell infiltration                         \- Ascites evacuation                  
                               HHV8 infection                              NRH -- Ascites                                \- Potassium sparing diuretics             
                       Multicentric Castleman'sdisease          Splenomegaly - Lymphnode enlargement                 Resolution of clinical manifestations          
                                                                                                                      Persistent NRH without complication           
                                                                            Pancytopenia                                             Alive                          
  2           M/47              HIV infection            Hepatomegaly with liver CD8^+^T-cell infiltration                            ART                                3
                            Chronic HCV infection                      Lymph node enlargement                        Resolution of clinical manifestations          
                         Autoimmune hemolyticanemia                      Hyperlymphocytosis                                 Died of splenic rupture                 
                                                                            Eosinophilia                                                                            
  3           M/49              HIV infection                       Acute interstitial nephritis              Boluses of methylprednisolone,prednisone 1 mg/kg/day       12
                                    DILS                 Cervicothoracic myelitis andlymphocytic meningitis                    ART after 1 month                    
                                                                         Hyperlymphocytosis                     Complete response in 2 weeks.Steroid dependence     
                                                                   Hypergammaglobulinemia 76 g/L                                     Alive                          

Clinical features. M: male. HIV: human immunodeficiency virus. HBV: hepatitis B virus. HCV: hepatitis C virus. HHV8: human herpes virus 8. DILS: diffuse infiltration of CD8^+^ T-cell lymphocytes syndrome. NRH: nodular regenerative hyperplasia. ART: antiretroviral therapy. FU: follow-up.

Materials and Methods {#s2}
=====================

Patients were retrospectively included from May, 2006 to May, 2012. Patients were recruited non-selectively from Hematology, Internal Medicine and Infectious Diseases Departments of Hôpital Saint-Antoine. The study was approved by the institutional review board of Hôpital Saint-Antoine and written informed consent was obtained from patients. Patients had to display a symptomatic organ infiltration by CD8^+^ T-cells, and/or at least one cytopenia, in association with a significant CD8^+^ T-cell expansion in peripheral blood or in bone marrow (\>50% of total lymphocyte count and/or a CD8^+^/CD57^+^ T-cell expansion \>30% of total lymphocyte count), for at least 3 months. Patients with a peripheral blood or in bone marrow TCRγδ^+^/CD57^+^ T-cell expansion (\>5% of total lymphocyte count) were also considered. Patients were classified according to their clinical presentation. Underlying conditions and medications were systematically recorded. Patients presenting an isolated CD8^+^ T-cell expansion and/or a CD8^+^/CD57^+^ T-cell expansion, but neither tissue infiltration nor cytopenia were not retained in the present study. Patient 3 was reported in a previous work [@pone.0091505-Zafrani1].

10.1371/journal.pone.0091505.t002

###### CD8^+^ T-cell expansion with tissue infiltration in the context of HIV infection.

![](pone.0091505.t002){#pone-0091505-t002-2}

  Patient    HIV load(log/mL)   PBL/mm^3^   LGL onblood smear   CD4^+^PBL/mm^3^ (%)[\*](#nt103){ref-type="table-fn"}   CD8^+^PBL/mm3 (%)[\*](#nt103){ref-type="table-fn"}   CD4^+^/CD8^+^ratio[\*](#nt103){ref-type="table-fn"}   CD8^+^/CD57^+^PBL/mm^3^ (%)[\*](#nt103){ref-type="table-fn"}   ANC/ mm^3^   Hb g/dL   Platelets/ mm^3^    Clonality    STATSH2
  --------- ------------------ ----------- ------------------- ------------------------------------------------------ ---------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------- ------------ --------- ------------------ ------------- ---------
  1                3.1            2100             Yes                                378 (18)                                             1365 (65)                                               0.28                                                     987 (47)                                1240        8.2          48000         Polyclonal      WT
  2                4.7            5360             Yes                               1130 (21)                                             2840 (53)                                               0.45                                                    1290 (24)                                4170        11           70000         Oligoclonal     WT
  3                4.6            5000             NA                                1150 (23)                                             3388 (68)                                               0.33                                                        NA                                   3500         9           276000        Oligoclonal     NA

Biological features.

\*performed from PBL immunophenotyping. HIV: human immunodeficiency virus. PBL: peripheral blood lymphocytes. LGL: large granular lymphocytes. ANC: absolute neutrophil count. Hb: hemoglobin. STAT: [S]{.ul}ignal [T]{.ul}ransducer and [A]{.ul}ctivator of [T]{.ul}ranscription. SH2: Src homology-2. WT: wild type. NA: not available.

10.1371/journal.pone.0091505.t003

###### CD8^+^ T-cell expansion with tissue infiltration without HIV infection.

![](pone.0091505.t003){#pone-0091505-t003-3}

  Patient    Sex/Age            Underlying conditions                        Clinical manifestations                           Treatment and outcome                 FU(months)
  --------- --------- ------------------------------------------ ----------------------------------------------- -------------------------------------------------- ------------
  4           F/67               Mantle cell lymphoma                      Consciousness disturbances                        Interruption of rituximab                   44
                            Hypogammaglobulinemia(2.2 g/L)        Aseptic meningitis with CD8^+^T-cells on CSF                          IVIG                        
                                Rituximab maintenance                                 Fever                             Resolution of clinicalmanifestations        
                                                                                    Diarrhea                                           Alive                        
                                                                               Hyperlymphocytosis                                                                   
  5           F/67     Splenic lymphoma withvillous lymphocytes                      Wasting                         Interruption of rituximaband chemotherapy           41
                             Hypogammaglobulinemia(3 g/L)         Diarrhea with CD8^+^ T-cellcolic infiltration                         IVIG                        
                                     FCR regimen                        Ascites with CD8^+^T-cells -- NRH         Resolution of clinicalmanifestations; persistent  
                                                                                  Pancytopenia                                NRH without complication              
                                                                                                                                       Alive                        

Clinical features. F: female. FCR: Fludarabine, cyclophosphamide and rituximab. CSF: cerebrospinal fluid. NRH: nodular regenative hyperplasia. IVIG: intravenous immunoglobulins. FU: follow-up.

10.1371/journal.pone.0091505.t004

###### CD8^+^ T-cell expansion with tissue infiltration without HIV infection.

![](pone.0091505.t004){#pone-0091505-t004-4}

  Patient    PBL/mm^3^   LGL onblood smear   CD8^+^ PBL/mm^3^ (%)[\*](#nt106){ref-type="table-fn"}   CD4^+^/CD8^+^ratio[\*](#nt106){ref-type="table-fn"}   Blood and BMCD8^+^/CD57^+/^mm^3^ (%)[\*](#nt106){ref-type="table-fn"}   ANC/mm^3^   Hbg/dL   Platelets/mm^3^    Clonality    STATSH2
  --------- ----------- ------------------- ------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------- ----------- -------- ----------------- ------------- ---------
  4            11410            Yes                                9360 (82)                                                0.12                                                     Blood: 7760 (68)                                1710       11.3        168000        Oligoclonal     WT
                                                                                                                                                                                         BM : 72%                                                                                      
  5             460             Yes                                270 (50)                                                 0.64                                                      Blood: 270 (50)                                 940       7.8          30000        Polyclonal      WT

Biological features.

\* performed from PBL immunophenotyping. PBL: peripheral blood lymphocytes. BM: bone marrow. LGL: large granular lymphocytes. ANC: absolute neutrophil count. Hb: hemoglobin. STAT: [S]{.ul}ignal [T]{.ul}ransducer and [A]{.ul}ctivator of [T]{.ul}ranscription. SH2: Src homology-2. WT: wild type.

Patients were evaluated with routine laboratory tests, including blood cell count, bone marrow aspirate and/or bone marrow biopsy. A blood smear with morphologic examination was carried out on all patients. All patients had serologies for acute viral infections (Epstein-Barr virus \[EBV\], cytomegalovirus \[CMV\], hepatitis B \[HBV\] and C \[HCV\] viruses), as well as for HIV and HTLV-1. CMV reactivation was assessed by genome amplification in blood. In patients with severe neutropenia, anti-surface neutrophil autoantibodies were detected with granulocyte immunofluorescence (GIFT) and with granulocyte agglutination test (GAT) [@pone.0091505-Coppo2]. Detection of anti-neutrophil cytoplasm antibodies (ANCA) and identification of their specificities were performed as reported elsewhere [@pone.0091505-Coppo2].

Lymphocytes immunophenotyping was performed from peripheral blood, ascites or cerebrospinal fluid after mononuclear cell labeling with the following monoclonal antibodies according to standard procedures: CD2, CD3, CD4, CD8, CD14, CD16, CD25, CD45RA, CD45RO, CD56, CD57, TCRαβ, TCRγδ and anti-HLA-DR. Cytogenetic analysis and clonality analysis of blood lymphocytes were performed as previously described [@pone.0091505-Coppo1].

10.1371/journal.pone.0091505.t005

###### CD4^+^/CD8^+^ ratio in infiltrated organs.

![](pone.0091505.t005){#pone-0091505-t005-5}

  Patient    Figure          CD4^+^/CD8^+^ ratio
  --------- -------- ------------------------------------
  1            1A                   0.105
               1C                   0.007
               1D                    0.54
               1F                    0.13
  2            1E                    0.03
               1H     0[\*](#nt107){ref-type="table-fn"}
  5            1B                    0.09
               1G                   0.074

\*CD4^+^/CD8^+^ ratio was 0/141.

10.1371/journal.pone.0091505.t006

###### Agranulocytosis and PRCA-associated CD8^+^ T-cell expansion.

![](pone.0091505.t006){#pone-0091505-t006-6}

  Patient    Sex/Age                 Underlying conditions                                   Clinical manifestations                                    Treatment and outcome                   FU(months)
  --------- --------- ---------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------ ------------
  6           F/68                    Rheumatoid arthritis                                         Splenomegaly                                                 G-CSF                               32
                                       Sjogren's syndrome                                        Agranulocytosis                                             ANC recovery                      
                                        Type 2 diabetes                     Myeloid maturational arrest(Myelocyte-metamyelocyte stage)             1 episode of febrile neutropenia            
                                                                                             Chronic ulcers, osteitis                                Died of pulmonary carcinoma               
  7           M/57              Allo-SCT for AML 3 years before                                  Agranulocytosis                                         Spontaneous recovery                       64
                                Hypogammaglobulinemia (2.5 g/L)                                  Thrombocytopenia                                   Persistent hyperlymphocytosis              
                                                                                                Hyperlymphocytosis                                              Alive                          
  8           F/66                    Rheumatoid arthritis                                       Agranulocytosis                                      Cyclophosphamide+rituximab                    9
                                                                            Myeloid maturational arrest(Myelocyte-metamyelocyte stage)       *E. coli*-bacteriemia, persistantneutropenia      
                                                                                                                                                                Alive                          
  9           M/44                       HCV infection                                   ANCA-associated agranulocytosis                                        G-CSF                               3
                                                                                             Acute dermo-hypodermitis                                    ANC recovery; alive                   
                                                                            Myeloid maturational arrest(Myelocyte-metamyelocyte stage)                                                         
  10          F/25                    Cutaneous ichtyosis                                        Mild neutropenia                                    Failure of IVIG and steroids                   39
                                                                                      Pure red cell aplasia with BM fibrosis                              MTX - CsA -- rEPO                    
                                                                                                                                                    Hematological recovery; alive              
  11          F/56                         Urticaria                                     ANCA-associated agranulocytosis                               CsA - G-CSF -- Steroids                      3
                                       Raynaud phenomenon                   Myeloid maturational arrest(Promyelocyte-myelocyte stage)    ANC recovery - resolution ofarthralgia and urticaria  
                                         Polyarthritis                                        Hypergammaglobulinemia                                            Alive                          
  12          F/67           Renal transplantation(IgA nephropathy)                           Pure red cell aplasia                                     Rapamycin interruption                      12
                       Immunosuppressive therapy:rapamycin and tacrolimus                        BM infiltration                                       Failure of rEPO and IVIG                
                                                                                                Hyperlymphocytosis                               Cyclophosphamide-relatedneutropenia           
                                                                                                                                                  Persistent anemia; RBCtransfusions           
                                                                                                                                                                Alive                          
  13          F/74                    Rheumatoid arthritis                                    Pure red cell aplasia                                          MTX -- rEPO                            46
                                                                                                 BM infiltration                                       Transfusion independence                
                                                                                                Hyperlymphocytosis                                              Alive                          
                                                                                                  Thrombocytosis                                                                               
  14          F/70                  Myelodysplastic syndrome                                   Rectal infiltration                                       MTX and CsA failure                        24
                                                                                                 Agranulocytosis                                              MMF -- MTX                       
                                                                                                      Anemia                                                Developed AML                      
                                                                                                                                                                 Died                          

Clinical features. F: female. M: male. Allo-SCT: allogeneic hematopoietic stem cell transplantation. AML: acute myeloblastic leukemia. HCV: hepatitis C virus. ANCA: anti-neutrophil cytoplasm antibodies. BM: bone marrow. ANC: absolute neutrophil count. *E. coli*: *Escherichia coli*. MTX: methotrexate. CsA: cyclosporine A. MMF: mycofenolate mofetil. G-CSF: granulocyte-colony stimulating factor. rEPO: recombinant erythropoietin. IVIG: intravenous immunoglobulins. RBC: red blood cells. FU: follow-up.

10.1371/journal.pone.0091505.t007

###### Agranulocytosis and PRCA-associated CD8^+^ T-cell expansion.

![](pone.0091505.t007){#pone-0091505-t007-7}

  Patient    PBL/mm^3^   LGL onblood smear   Blood and BM CD8^+^lymphocytes/mm^3^ (%)[\*](#nt110){ref-type="table-fn"}   CD4^+^/CD8^+^ [\*](#nt110){ref-type="table-fn"}   Blood and BM CD8^+^/CD57^+/^mm^3^ (%)[\*](#nt110){ref-type="table-fn"}   ANC/mm^3^   Hbg/dL   Platelets/mm^3^    Clonality    STAT3SH2
  --------- ----------- ------------------- --------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------ ----------- -------- ----------------- ------------- ----------
  6            1950             Yes                                       Blood: 819 (42)                                                     0.67                                                    Blood: 555 (32)                                  200       10.3        188000        Polyclonal       WT
                                                                              BM: NA                                                                                                         TCRγδ^+^/CD57^+^T cells: 492 (22)                                                                          
  7            9330             Yes                                      Blood: 8676 (93)                                                     0.03                                                    Blood: 8210 (88)                                  0        11.2        105000        Oligoclonal      WT
                                                                              BM: 82%                                                                                                                     BM: 67%                                                                                       
  8            6400             Yes                                      Blood: 3970 (62)                                                      0.5                                                    Blood: 3200 (50)                                 160       11,8        238000          Clonal       Y640F
                                                                              BM: 68%                                                                                                                     BM: 54%                                                                                       
  9            2220             No                                       Blood: 1984 (51)                                                     0.63                                                    Blood: 1400 (36)                                  0        12.5        288000        Oligoclonal      WT
                                                                              BM: 50%                                                                                                                     BM: 37%                                                                                       
  10           1460             Yes                                       Blood: 701 (48)                                                                                                             Blood: 438 (30)                                 1460       6,2         236000          Clonal       Y640F
                                                                              BM: 51%                                                                                                                     BM: 40%                                                                                       
  11           2100             Yes                                       Blood: 731 (34)                                                     0.57                                                    Blood: 301 (14)                                  100       14.3        168000        Polyclonal       WT
                                                                              BM: 38%                                                                                                 BM: 51% including 8%of TCRγδ^+^/CD57^+^ T cells                                                                   
  12           6400             No                                       Blood: 3840 (60)                                                      0.5                                                    Blood: 2048 (32)                                3300       5.1         221000            NA           NA
                                                                              BM: NA                                                                                                                                                                                                                    
  13           5360             No                                           Blood: NA                                                                                                                       NA                                       1650       7.1         482000        Oligoclonal      WT
                                                                              BM: 86%                                                                                                                     BM: 38%                                                                                       
  14            830             No                                        Blood: 315 (38)                                                      1.4                                                    Blood: 280 (34)                                  10        8.2         823000        Polyclonal       NA
                                                                              BM: 75%                                                                                                                                                                                                                   

Biological features.

\*performed from PBL immunophenotyping. PBL: peripheral blood lymphocytes. LGL: large granular lymphocytes. BM: bone marrow. TCR: T-cell receptor. ANC: absolute neutrophil count. Hb: hemoglobin. STAT: [S]{.ul}ignal [T]{.ul}ransducer and [A]{.ul}ctivator of [T]{.ul}ranscription. SH2: Src homology-2. WT: wild type. NA: not available.

Clonality of expansion was routinely tested using TCR-γ Polymerase Chain Reaction (PCR) followed by fragment length analysis on 3500 xL Dx Genetic Analyser (Applied Biosystems®) according to Biomed-2 standardization protocol [@pone.0091505-vanDongen1]. *STAT3* exon 21 mutations were screened by PCR and high resolution melting curve analysis on LightCycler® 480 instrument (Roche Applied Science) followed by a purification step of amplicons and direct sequencing on 3500 xL Dx Genetic Analyser (primers and conditions available on request).

Median (range) was determined for all continuous variables. Wilcoxon's test was used to compare continuous variables.

Results {#s3}
=======

General Features {#s3a}
----------------

Patients (9 women/5 men) were 65 year-old (range, 25--74). Six patients had ≥1 symptomatic organ infiltration, and 9 had ≥1 cytopenia with a CD8^+^ (\>50% of total lymphocyte count) and/or a CD8^+^/CD57^+^ (\>30% of total lymphocyte count) T-cell expansion for at least 3 months. One patient had both manifestations. Median peripheral blood lymphocyte count was 4.45 G/L (range, 0.53--11.4 G/L). Seven patients had a peripheral blood lymphocytosis \>4 G/L. Median peripheral blood CD8^+^ T-cell count was 1.98 G/L (range, 0.27--9.36 G/L); 7 patients had a CD8^+^ T-cell count \>1.5 G/L. CD8^+^/CD57^+^ T-cells involved 35% (range, 14--88%) of total peripheral blood lymphocytes. Bone marrow CD8^+^/CD57^+^ T-cells in patients with cytopenia represented 60% (range, 38--86%) of total bone marrow lymphocytes. Two patients with cytopenia and a CD8^+^/CD57^+^ T-cell expansion in blood or in bone marrow also had a TCRγδ^+^/CD57^+^ polyclonal T-cell expansion, which resulted in a total CD57^+^ T-cell count of \>50% in blood or \>30% in bone marrow. In all cases, the CD4^+^/CD8^+^ ratio was \<2. There was no significant association between peripheral blood lymphocyte count and organ infiltration (median, 5 G/L \[range, 0.46--11.4 G/L\] in patients with organ infiltration *versus* 2.22 G/L \[range, 0.83--9.33\] in patients without organ infiltration, p = 0.70). Cytogenetical analysis was performed in four patients and was found normal. T-cells were oligoclonal, polyclonal and clonal in 6 cases, 5 cases and in 2 cases, respectively. The analysis of exon 21 of STAT3 was performed in 12 patients. The Y640F mutation in the SH2 domain of STAT3 was found in 2 patients with clonal TCRγ rearrangement and immunological cytopenias (patients 8 and 10), consistent with the diagnosis of LGL leukemia [@pone.0091505-Koskela1]. No patient had evidence of CMV reactivation.

The median follow-up was 25 months (range, 3--64 months).

CD8^+^ T-cell Expansion with Tissue Infiltration ([Table 1](#pone-0091505-t001){ref-type="table"}, [2](#pone-0091505-t002){ref-type="table"}, [3](#pone-0091505-t003){ref-type="table"}, [4](#pone-0091505-t004){ref-type="table"}) {#s3b}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Three patients had a HIV infection for 8 years (5 months-20 years). Two patients had a past history of opportunistic disease: a multicentric Castleman disease (Patient 1), and pulmonary tuberculosis (Patient 3). Median CD4^+^ T cell count at time of CD8^+^ T-cell expansion diagnosis was 0.59 G/L (range, 0.35--1.131 G/L) and HIV RNA viral load was 4.6 Log/mL (range, 3--4.7 log/mL). CD8^+^ T-cell expansion resulted in a peripheral blood lymphocytosis in 2 cases (Patients 2 and 3). Organ infiltration involved the colon and the rectum, the kidney, the cerebrospinal fluid, the skin (1 case each), the liver and lymph nodes (2 cases each) **(** [**Figure 1A, 1C--F and 1H**](#pone-0091505-g001){ref-type="fig"} **,** [**Table 5**](#pone-0091505-t005){ref-type="table"} **).** One patient with renal infiltration also had a cervicothoracic myelitis in association with a lymphocytic meningitis, consistent with the diagnosis of DILS [@pone.0091505-Zafrani1]. Symptoms resolved in all 3 cases with symptomatic measures and efficient ART. The patient with the DILS also required a long term steroid therapy for a steroid-dependent disease [@pone.0091505-Zafrani1].

![Histopathological findings on patients with CD8^+^ expansion and organ infiltration.\
CD8 immunostaining on colon (**A**, patient 1; **B**, patient 5), rectum (**C**, patient 1), lymph node (**D**, patient 1, **E**, patient 2), skin (**F**, patient 1) and liver (**G**, patient 5, **H**, patient 2), showing that the lamina propria, the germinal center, the derma and the liver lobules, respectively, are massively infiltrated by CD8^+^ T-cell lymphocytes, whereas CD4^+^ T cell lymphocytes are rare or absent. CD4 was revealed by DAB (brown), and CD8 by Fast Red (magnification x400).](pone.0091505.g001){#pone-0091505-g001}

Three patients with a CD8^+^ T-cell expansion-associated tissue infiltration were HIV-negative. Two patients were receiving a maintenance treatment with rituximab (Patient 4) or a fludarabine-based chemotherapy associated with rituximab (Patient 5) for a low grade lymphoma that was in complete remission at time of CD8^+^ T-cell expansion diagnosis. Both patients had a persistent hypogammaglobulinemia. In patient 4, CD8^+^ T-cell expansion occurred 1 year after maintenance treatment with rituximab was started; it was revealed by aseptic CD8^+^ lymphocytic meningitis with fever, diarrhea and lymphocytosis with bone marrow infiltration. No herpes virus infection was evidenced. The patient was treated successfully with intravenous immunoglobulins (0.5 g/kg every 3 weeks for 6 months) and rituximab was suspended. CNS features resolved completely and CD8^+^ T-cell lymphocytes disappeared from CSF. Patient 5 developed an unusually severe pancytopenia during treatment, associated with a persistent diarrhea and a portal hypertension with ascites as a result of a regenerative nodular hyperplasia. CD8^+^ T-cell lymphocytes were found in the ascites liquid, in peripheral blood and in bone marrow. A colon biopsy evidenced a mucosal CD8^+^ T-cell infiltration ([**Figure 1B and 1G**](#pone-0091505-g001){ref-type="fig"} **,** [**Table 5**](#pone-0091505-t005){ref-type="table"}). She dramatically improved with intravenous immunoglobulins (0.5 g/kg every 3 weeks for 6 months), with a resolution of diarrhea and a blood cell count recovery. The third patient had a myelodysplastic syndrome with agranulocytosis (detailed below). She had a persistent diarrhea that revealed a CD8^+^ T-cell infiltration in the lamina propria of the colon.

CD8^+^ T-cell Expansion with CIN and PRCA ([Table 6](#pone-0091505-t006){ref-type="table"}--[7](#pone-0091505-t007){ref-type="table"}) {#s3c}
--------------------------------------------------------------------------------------------------------------------------------------

Six patients had an agranulocytosis consistent with a CIN, with no tissue involvement other than blood and/or bone marrow in all but one patient, who also had a rectal infiltration. Patients 7 and 14 also had mild anemia and thrombocytopenia (1 case each). Four patients had an associated disease. Agranulocytosis was revealed by an infectious process in 2 cases: in one case (Patient 9), a dermo-hypodermitis with 2 episodes of severe pneumonia that required mechanical ventilation; in the other case (Patient 14), a febrile neutropenia in a context of myelodysplastic syndrome with a persistent diarrhea that revealed a CD8^+^ T-cell infiltration in the lamina propria of the rectum ([**Figure 2A**](#pone-0091505-g002){ref-type="fig"} **,** [**Table 8**](#pone-0091505-t008){ref-type="table"}). In the 4 other cases, agranulocytosis was identified fortuitously while patients were followed-up for an associated condition. Median ANC was 0.06 G/L (range, 0--0.2 G/L). CD8^+^ T-cell expansion resulted in a peripheral blood lymphocytosis in 4 cases (Patients 7, 8, 12, 13). Bone marrow smear disclosed a myeloid maturation arrest in all cases. Bone marrow biopsy was performed in 2 patients and disclosed a CD8^+^ T-cell infiltration ([**Figure 2B--C**](#pone-0091505-g002){ref-type="fig"} **,** [**Table 8**](#pone-0091505-t008){ref-type="table"}). Anti-neutrophil antibodies were sought in all patients and were consistently found mildly positive (1+). ANCA were positive in 2/6 patients, consistent with the diagnosis of CIN [@pone.0091505-Coppo2], [@pone.0091505-Loschi1]. Titer was 1/40 and 1/320. They were directed against PR3 in one case, whereas in the other case the specificity could not be identified.

![Histopathological findings on patients with CD8^+^ expansion and cytopenia.\
CD8 immunostaining on rectum (**A**, patient 14) and bone marrow (**B**, patient 14; **C**, patient 10), showing infiltration by numerous CD8^+^T-cell lymphocytes with few CD4^+^ T cells. CD4 was revealed by DAB (brown), and CD8 by Fast Red (magnification x400).](pone.0091505.g002){#pone-0091505-g002}

10.1371/journal.pone.0091505.t008

###### CD4^+^/CD8^+^ ratio in infiltrated organs in patients with agranulocytosis and PRCA-associated CD8^+^ T-cell expansion.

![](pone.0091505.t008){#pone-0091505-t008-8}

  Patient    Figure   CD4^+^/CD8^+^ ratio
  --------- -------- ---------------------
  10           2C             0.1
  14           2A            0.009
               2B            0.24

Three patients had a PRCA. In 2 cases, it was associated with a connective tissue disease; in the third case, it occurred in a context of renal transplantation performed 27 years before. Median hemoglobin level was 5.7 g/dL (range, 5.1--6.2). PRCA was characterized by a normal growth of erythroblasts *in vitro* with erythropoietin, ruling out an intrinsic defect. No antibodies directed against erythropoietin were found. No patient had thymoma and Parvovirus B19 was negative in all cases.

Five patients had a long standing history of autoimmune disease: a rheumatoid arthritis (Patients 6, 8 and 13), a Raynaud's phenomenon (Patient 11) and an ichtyosis (Patient 10).

Two patients with agranulocytosis were treated successfully with G-CSF. In a third case, G-CSF allowed a mild increase in neutrophil count. However, a treatment with cyclosporin A and steroids led to durable neutrophil count recovery. One patient was treated successfully with oral cyclophosphamide. One patient with a history of hematopoietic stem cell transplantation recovered neutrophil count spontaneously. The last patient, with a myelodysplastic syndrome, recovered transiently neutrophil count with methotrexate and cyclosporin A before she developed an acute leukemia 2 months later.

Two patients with PRCA were treated successfully with methotrexate, associated with cyclosporine A and recombinant erythropoietin in one case, with a recovery of hemoglobin level. In a third patient, treatment with intravenous immunoglobulins and cyclophosphamide was unsuccessful and the patient remains transfused every 3 weeks.

Discussion {#s4}
==========

In our study, patients with a chronic CD8^+^ T-cell expansion presented with two main features. The first was a pseudotumoral organ infiltration by non clonal cells that typically occurred in immunocompromised patients, such as in patients with a HIV infection or in patients receiving an immunosuppressive treatment. The second presentation was an immune cytopenia, typically an agranulocytosis or a PRCA, which may result from either a LGL leukemia [@pone.0091505-Lamy1], or a non clonal expansion in blood and/or bone marrow.

CD8^+^ T-cell Expansion in Immunocompromised Patients {#s4a}
-----------------------------------------------------

We identified a CD8^+^ T-cell expansion with organ infiltration in patients with a context of immune deficiency, i.e., a HIV infection and a B cell depletion-based immunosuppressive treatment for a lymphoid malignancy. Studies associated HIV infection with an expansion of CD8^+^ T-cells directed against the virus early in the course of the disease. This expansion is usually transient and followed by a decrease in CD8^+^ T-cell count. The prevalence of a persistent peripheral blood CD8^+^ T-cell lymphocytosis varies from 0.3% to 4.6%, and was associated with a slower progression of the infection and a prolonged survival [@pone.0091505-Smith1], which is in accordance with our findings since one patient had a HIV infection for more than 20 years. On the opposite, others associated such expansion of activated CD8^+^/HLA DR^+^ T-cells with chronic diseases linked to inflammatory damage and increased morbidity and mortality [@pone.0091505-Dock1], [@pone.0091505-Chou1]. In HIV-infected patients, CD8^+^ T-cell lymphocytosis could be observed in the context of DILS [@pone.0091505-Itescu2], [@pone.0091505-Itescu3], [@pone.0091505-Basu1]. In our patients, parotid gland swelling, a typical feature of DILS, was not present. Rather, organ enlargement involved prominently lymphoid organs with pseudotumoral splenomegaly and hepatomegaly [@pone.0091505-Oksenhendler1], and non-lymphoid organs such as the digestive tract, the skin, the CNS and kidneys. Therefore, our findings widen the spectrum of CD8^+^ T-cell organ infiltration in HIV-infected patients. Importantly, the identification of a non clonal CD8^+^ T-cell expansion, and more particularly if a majority of CD8^+^ T-cells express the CD57 antigen, may help to rule out the diagnosis of lymphoid malignancy in these patients and avoid performing a splenectomy or other invasive diagnostic explorations. In this context, the diagnostic value of the fluorodeoxyglucose positron-emitting tomography deserves evaluation.

We report a CD8^+^ T-cell expansion with organ infiltration in 2 patients treated with immunosuppressive drugs. Interestingly, both patients shared similar features: an advanced age (67 year-old both), organ infiltration (i.e., lymphocytic meningitis in 1 case and a chronic diarrhea with a digestive tract infiltration and ascitis with CD8^+^ T-cells in the other), a severe hypogammaglobulinemia, and an immunosuppressive chemotherapy including multiple infusions of rituximab. These features strongly suggest a role for infectious agents occurring within an underlying immune deficiency (an advanced age, a profound hypogammaglobulinemia and a prolonged treatment with immunosuppressive drugs), and a role for an antigen-driven response in the occurrence of CD8^+^ T-cell expansion. Consistent with this hypothesis, the outcome was remarkably favorable in both cases with rituximab interruption and intravenous immunoglobulins. Moreover, this clinical presentation was reminiscent of those observed in DILS in the era of efficient ART, with a predominance of extraglandular manifestations [@pone.0091505-Basu1]. Cases of CD8^+^ T-cell expansions in the setting of hypogammaglobulinemia and rituximab treatment still remain poorly reported in literature [@pone.0091505-Ferrero1]--[@pone.0091505-Sato1]; therefore, clinicians should be aware about this diagnosis.

The mechanisms leading to non clonal, reactive CD8^+^ T-cell expansions in these settings are not fully understood. Animal models strongly argue for an important role of an underlying immune deficiency, which may result in a dysfunction in the usual contraction process that follows the expansion of activated CD8^+^ T-lymphocytes after an antigenic challenge, either autologous in a context of autoimmune disease or exogenous in a context of chronic infectious disease. Moreover, this dysfunctional process may alter the repartition of immunodominant T-cell populations, accounting for the predominance of expanded clones in these patients [@pone.0091505-Badovinac1], [@pone.0091505-Badovinac2]. In the specific case of DILS, Itescu *et al*. suggested that some immunogenetically distinct individuals were responding to HIV infection by developing 'reactive' circulating CD8^+^ lymphocytosis, and that lymphocytes were sequestered into the different organs by interaction with accessory molecules. However, it cannot be excluded that the expansion of CD8^+^ T-cells could also be due to other viral coinfectants such as EBV or HTLV-1 [@pone.0091505-Itescu3].

CIN and PRCA-associated CD8^+^ T-cell Expansion {#s4b}
-----------------------------------------------

In adults, CIN and autoimmune PRCA are typically mediated by autoimmune cytotoxic T-cells through the release of inhibitory molecules [@pone.0091505-Capsoni1], [@pone.0091505-Akhtari1]. They can be variably associated with conditions such as rheumatoid arthritis and Felty's syndrome, Sjogren's syndrome and systemic lupus erythematosus, as well as chronic GVHD, lymphoid malignancies and primary immune deficiencies ([@pone.0091505-Coppo1]--[@pone.0091505-Akhtari1]; present study). These conditions may occur in the context of LGL leukemia; alternatively, they may represent exclusion diagnoses made after the other causes of neutropenia and PRCA have been excluded. In this context, the presence of reactive, oligoclonal CD8^+^ T-cells with features of LGL (which was termed the syndrome of T8 hyperlymphocytosis by previous authors, [@pone.0091505-Nitta1], [@pone.0091505-GrillotCourvalin1]) or more rarely TCRγδ^+^/CD8^+^ T-cells ([@pone.0091505-Roden1], present study) can be of diagnostic help in patients explored for a chronic neutropenia or a PRCA of unexplained origin. Noteworthy, CD8^+^ T-cells expansion may not be evident from morphological examination of the bone marrow aspirate or biopsy, from flow cytometric analysis of the aspirate, or from the peripheral blood lymphocyte count. Therefore, immunohistochemical analysis should be performed routinely in these rare conditions [@pone.0091505-Ramadan1]. Interestingly, it is not excluded that oligoclonal CD8^+^ T-cell expansions and LGL leukemia may represent a continuous spectrum in which oligoclonal, chronically stimulated CD8^+^ lymphocytes may finally acquire oncogenic events until an overt LGL leukemia develops. Recently, the pathophysiological mechanism of LGL leukemia was outstandingly improved with the recent identification of acquired mutations of the SH2 domain of *STAT3* and *STAT5b* in 40% and 2% of cases, respectively [@pone.0091505-Koskela1], [@pone.0091505-Rajala1], and the search for these mutations may help to distinguish LGL leukemia from reactive CD8^+^ T-cell expansions.

A pathogenic CD8^+^ T-cell expansion was associated with anemia and/or neutropenia in allo-SCT ([@pone.0091505-Mohty1]; present study) through a HLA class II-restricted inhibition of bone marrow erythroblastic and/or granulocytic progenitors, respectively [@pone.0091505-Vinci1]. In this context, CD8^+^ T-cell expansions were associated with a prolonged relapse free survival, suggesting that CD8^+^ T-cells recognize epitopes in malignant cells [@pone.0091505-Mohty1]. Therefore, their identification in this context may be of prognostic value. In this context, CD8^+^ T-cells were reported to have a suppressive effect on hematopoiesis, which could be the consequence of an allogeneic reaction [@pone.0091505-Vinci1]. Similarly, self-reactive CD8^+^ T-cells may recognize autologous antigens, and could result in CIN [@pone.0091505-GrillotCourvalin1].

The identification of a CD8^+^ T-cell expansion was also observed in myeloid malignancies such as acute leukemias and myelodysplastic syndromes. In these latter, CD8^+^ T-cells were found to recognize self-antigens in up to 80% of cases, which may account for the severe cytopenias we observed in one patient of the present series. Interestingly, somatic mutations of the SH2 domain of *STAT3* were identified in the lymphoid compartment in patients with myelodysplastic syndrome and profound neutropenia, consistent with the presence of subclinical T-cell clones which may be involved in the development of hypocellularity. In these patients, CD8^+^ T-cell expansions may be associated with a better response to immunosuppressive treatments [@pone.0091505-Jerez1].

In conclusion, CD8^+^ T-cell expansions can result in the infiltration of various organs, including blood and bone marrow. They typically involve the senescent CD8^+^/CD57^+^ T-cells subpopulation and should therefore be considered as a specific syndrome. The search for a CD8^+^ T-cell expansion should be performed in immunocompromised patients who present with a symptomatic organ infiltration, including blood and bone marrow when patients present with unexplained cytopenia(s). The study of the underlying pathological context, the cytogenetical and TCR-γ clonality analyses and the search of mutations in the SH2 domain of *STAT3* and *STAT5b* should help to distinguish LGL leukemia or other malignant lymphomas from non clonal CD8^+^ T-cell expansions. In patients with a smoldering organ enlargement, the identification of a CD8^+^ T-cell expansion can help to rule out a lymphoid malignancy and to avoid invasive explorations, whereas in patients with unexplained cytopenia, such a population suggests an autoimmune process. The identification of an organ enlargement attributed to a CD8^+^ T-cell expansion may also have therapeutical consequences. This condition may therefore represent an indication to reevaluate or initiate an efficient ART in HIV infected patients, in association with steroids in selected cases; in immunocompromised non HIV-infected patients, intravenous immunoglobulins (and, more generally, the correction of the immune deficiency) may help to resolve clinical manifestations. In patients with a symptomatic cytopenia, the identification of a CD8^+^ T-cell expansion may require hematopoietic growth factors and/or immunomodulatory drugs. Though the monocentric design of our study represents a limitation, it allowed our patients to be explored homogeneously. Another limitation of this study is the small number of reported patients. Consequently, our preliminary data require future prospective studies with a large screening of CD8^+^/±CD57^+^ T-cells in selected cohorts of patients with HIV infection and cytopenia to confirm their diagnostic and prognostic value, which could be incorporated in diagnostic and predictive scores.
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